Alexion

News

Alexion joins with Dicerna to develop RNAi therapies for com...

Alexion has announced a collaboration with Dicerna Pharmaceuticals to discover and develop RNA interference therapies for diseases caused by problems in the complement system.

News

Alexion buys rare diseases biotech Syntimmune for up to $1.2...

Alexion is to buy rare diseases biotech Syntimmune and its experimental drug for a rare kind of anaemia, in a deal worth up $1.2 billion.

News

Alexion prepares filings for new rare disease use for Soliri...

Alexion is preparing filings in major markets for its rare disease drug Soliris in a new indication after a positive readout in a rare neurological disease.

News

Alexion hastens review of successor to rare disease blockbus...

Alexion's rare disease drug Soliris is generating blockbuster-level sales – but the US biotech is rushing through development of a successor amid potential competition and U

News